Background/Aims: Myocardial apoptosis plays an important role in doxorubicin (Dox) cardiotoxicity. ) is suggested to function as an anti-fibrotic factor with potential therapeutic effects on cardiac fibrosis. However, it has not been shown whether there is an association between miR-29b and myocardial apoptosis. Methods: Male Wistar rats were transfected with miR-29b agomir by local delivery to the myocardium prior to Dox treatment. Rat cardiomyocytes were pretreated with miR-29b mimics or inhibitor followed by Dox incubation in vitro. Cardiac function and underlying mechanisms were evaluated by echocardiography, immunofluorescence, flow cytometry, real-time PCR, and western blotting. Results: Our results revealed that miR-29b is the only member of the miR-29 family that was significantly downregulated in myocardium from Dox-treated rats. Delivery of miR-29b agomir to myocardium resulted in a marked improvement of cardiac function. Terminal deoxynucleotidyl transferase dUTP nick end labeling staining showed that rescue of miR-29b expression inhibited Dox-induced myocardial apoptosis, concomitantly with increased Bcl-2 expression and decreased Bax expression and caspase-3 activity. In vitro, miR-29b overexpression mitigated, whereas inhibition of miR-29b promoted, Dox-induced cardiomyocyte apoptosis. Mechanistically, miR-29b negatively regulated Bax expression by directly targeting the 3′ untranslated region of Bax. In Dox-treated cardiomyocytes, upregulation of miR-29b resulted in a significant decrease in Bax expression, with an increase in Bcl-2 expression, accompanied by inhibition of mitochondrial membrane depolarization, cytochrome c release, and caspase activation. However, inhibition of miR-29b produced the opposite effects by further augmenting the effects of Dox. Conclusions: These data
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Introduction
Cancer is the second leading cause of death worldwide [1] . Over the past decade, despite survival rates improving due to advances in cancer biology and therapeutics, immunosuppressive and cytotoxic adverse effects still limit the therapeutic use of anticancer drugs [1] [2] [3] . Doxorubicin (Dox) is widely used for the treatment of solid tumors and hematologic malignancies [4, 5] . Unfortunately, the therapeutic index of this highly potent anti-neoplastic agent is reduced due to its cardiotoxicity, which may lead to severe cardiomyopathy and even cause heart failure and mortality [1, 6] . It is worth noting that the deterioration of cardiac function is mainly associated with myocardial apoptosis [7, 8] . Being terminally differentiated cells, cardiomyocytes are generally not replicative. Therefore, inhibiting cardiomyocyte apoptosis may be an effective approach to prevent the cardiotoxicity of Dox. However, the molecular mechanisms underlying the Dox-induced apoptosis in cardiomyocytes remain poorly understood.
MicroRNAs (miRs) are a class of endogenous, small (22 nucleotides in length), noncoding RNAs that post-transcriptionally regulate target gene expression by binding to the 3′ untranslated region (3′-UTR) [4] . There is evidence indicating that miRs functionally modulate a variety of physiological or pathological processes [9] [10] [11] . More importantly, clinical trials and animal experiments have demonstrated that miRs are potential regulators of the cardiotoxicity of Dox. Recent studies have shown that miR-30e, -208, and -21 ameliorate Dox-induced cardiomyocyte apoptosis, while miR-320a, -523-3p, -140, and -146a further enhance apoptosis [4, [11] [12] [13] [14] [15] [16] . These findings suggest that manipulation of miRs is a promising therapeutic approach. In the current study, we provide the first evidence to our knowledge identifying miR-29b (a member of miR-29 family) as an essential regulator of the mitochondria pathway, cardiomyocyte apoptosis, and Dox cardiotoxicity by directly targeting Bax, a gene critical for the activation of the intrinsic mitochondria pathway. Our data suggest that miR-29b is a potential novel therapeutic target for the treatment of Dox cardiotoxicity during chemotherapy.
Materials and Methods

Animal model
Male Wistar rats (250-300 g) were purchased from the Model Animal Research Center of Nanjing University (Nanjing, China). All animal experiments were performed according to the guidelines of the Institutional Animal Care and Use Committee of the Fourth Military University and approved by the Institutional Animal Ethics Committee. miR-29b agomir and mismatched agomir (MA) were designed and obtained from Obio Technology (Shanghai, China). Three days before Dox administration, rats were anesthetized with pentobarbital sodium (40 mg/kg, intraperitoneally [ip] ) and a lateral thoracotomy was performed. miR-29b agomir or MA (200 nmol/kg in a final volume of 200 μL) was injected into 10 sites at a depth of 1-2 mm in the left ventricular free wall with a 26-gauge syringe as previously described [17, 18] . After agomir delivery, rats were implanted with a mini osmotic pump (ALZET Model 2002, Cupertino, CA, USA) containing 200 μL of either saline (vehicle for Dox) or Dox at a dose of 30 mg/kg body weight, at a rate of 0.5 μL/h for 14 days.
Real-time PCR
Total RNA from myocardial tissues and cardiomyocytes was isolated using an RNAeasy Kit (Qiagen, Venlo, the Netherlands) according to the manufacturer's instructions. To measure miR-29a, miR-29b, and miR-29c expression, real-time PCR was performed on a 7500 Fast Real-Time PCR System (Applied Terminal deoxynucleotidyl transferase dUTP nick end labeling staining Cell apoptosis was measured by performing a terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay using an In Situ Cell Death Detection kit (Roche, Mannheim, Germany). The frozen sections were incubated with TUNEL Reaction Mixture at 37°C for 60 min. Cardiomyocytes were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, and incubated with TUNEL Reaction Mixture for 60 min at 37°C. The nuclei were counterstained with DAPI. Apoptotic cells were observed with a confocal microscope (FV1000). The percentage of TUNEL-positive cells was expressed as a ratio of stained apoptotic cells to total cell number.
Western blotting
The left ventricular anterior wall or cardiomyocytes were lysed by RIPA lysis buffer (Beyotime Institute of Biotechnology, Shanghai, China) containing protease inhibitor cocktail (Thermo Fisher Scientific Inc.). Intact mitochondria were isolated using a Mitochondria Isolation Kit (Thermo Fisher Scientific Inc.) according to the manufacturer's protocol. Protein concentration was determined using a Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA). Proteins were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis gels and transferred onto polyvinylidene fluoride membranes (Millipore, Burlington, MA, USA). Thereafter, the membranes were blocked in 5% non-fat milk and then incubated with primary antibodies against Bcl-2 (1:1000), Bax (1:1000), cytochrome c (1:500), caspase-9 (1:1000), caspase-3 (1:500), and PARP (all from Cell Signaling Technology, Danvers, MA, USA); and β-actin (1:2000) and Cox IV (1:1000) (both Santa Cruz Biotechnology). After incubation with horseradish peroxidase-conjugated secondary antibodies (Beyotime Institute of Biotechnology) for 1 h at room temperature, blots were visualized by an enhanced chemiluminescence system (Thermo Fisher Scientific Inc.). The intensity of bands was digitally quantified using densitometric analysis software (ImageJ 1.57, NIH, Bethesda, MD, USA).
Caspase-3 activity assay
Caspase-3 activity in myocardial tissue homogenates was measured using a colorimetric assay kit (Beyotime Institute of Biotechnology) according to the manufacturer's protocol.
Cell viability assay
The viability of cardiomyocytes was detected using the Cell Counting Kit-8 (CCK-8; Dojindo, Tokyo, Japan). The cells were seeded in 96-well plates at a density of 10 3 cells per well. After the cell treatment described above, CCK-8 reagent was added to the cells for 4 h at 37°C and 5% CO 2 . The absorbance was measured at a wavelength of 490 nm using a microplate reader (Bio-Tek, Winooski, VT, USA).
Apoptosis analysis by flow cytometry
Cardiomyocyte apoptosis was evaluated using the FITC-Annexin V Apoptosis Detection Kit (Beyotime Institute of Biotechnology) by flow cytometry according to the manufacturer's instructions. Cells were harvested for Annexin V-FITC and propidium iodide (PI) staining for 15 min at room temperature in the dark. The apoptotic cells were counted by flow cytometry (Accuri C6, BD Biosciences, San Jose, CA, USA).
Luciferase reporter assay
The wild-type rat Bax 3′-UTR (GenBank ID: NM_017059.2; hereafter referred to as the Bax 3′-UTR) was subcloned into the multiple cloning site of the pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega). The mutant 3′-UTR of the Bax gene was generated by substitution of 5 bp from the seed region of miR-29b. Cardiomyocytes were seeded in 96-well plates and co-transfected with luciferase reporter and miR-29b mimics or miR-29b inhibitor using Lipofectamine 2000. The cells were harvested 48 h later and the luciferase activity was assessed using the Dual-Luciferase Reporter Assay System (Promega).
Mitochondrial membrane potential assay
Mitochondrial membrane potential (MMP) was measured by 5, 5′,6, 6′-tetrachloro-1, 1′,3, 3′-tetraethyl-benza-midazolocarbocyanin iodide (JC-1, Invitrogen) fluorescence staining, an indicator of apoptosis. In healthy cells, JC-1 exhibits potential-dependent accumulation in mitochondria, indicated by red fluorescence. In apoptotic cells, the MMP is disrupted and the dye is released into the cytoplasm as a Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry monomer and emits green fluorescence. The ratio of red/green fluorescence intensity indicates the change in MMP. Cardiomyocytes were incubated with JC-1 working solution in the dark at 37°C for 15 min. After washing with PBS twice, the fluorescence was measured using a confocal microscope (FV1000).
Statistical analysis
All data are presented as the mean ± standard error of the mean and were compared by two-tailed Student's t test or one-way analysis of variance, followed by Bonferroni's multiple-comparison test. Statistical analysis was performed using SPSS 18.0 software (SPSS Inc., Chicago, IL, USA). P < 0.05 was considered statistically significant.
Results
miR-29b expression in myocardium is regulated by Dox
The miR-29 family comprises 3 miRs: miR-29a, miR-29b, and miR-29c. We first examined the expression pattern of the miR-29 family in myocardium. Real-time PCR results showed that the expression of miR-29b was approximately 4-fold higher than that of miR-29a and 8-fold higher than that of miR-29c (Fig. 1A) . miR-29a and miR-29c expression in myocardium was not significantly influenced by Dox administration (Fig. 1B and C ). Interestingly, with regard to miR-29b expression, Dox induced its downregulation in rat myocardium in a timedependent manner (Fig. 1D ). Further in situ hybridization analysis with the DIG-labeled miR29b probe also revealed decreased expression of miR-29b in myocardium of Dox-treated rats compared with vehicle-treated rats (Fig. 1E ). To further support the in vivo results, rat cardiomyocytes were treated with different concentrations of Dox and miR-29b expression was determined. Compared with the vehicle group, miR-29b expression was significantly decreased by exposure to 1 or 10 μmol/L Dox in cardiomyocytes (Fig. 1F ). These data suggest that miR-29b is the dominant member of the miR-29 family expressed in myocardium and that its expression is reduced in response to Dox-induced cardiotoxicity. 
Overexpression of miR-29b blocks Dox-induced myocardial injury
To investigate the role of miR-29b in the sequelae of Dox-induced cardiotoxicity, rats were treated with miR-29b agomir or MA prior to Dox administration. As shown in Fig. 2A , Dox insult resulted in a loss of cardiomyocyte membrane integrity, as evidenced by increased EBD-positive staining. However, miR-29b agomir treatment significantly decreased EBD-positive staining (Fig. 2B) . As a marker for cardiac injury, the release of LDH was measured. We observed that the serum LDH and cTnT concentrations in Dox-treated rats were higher than those of vehicle-treated rats, and miR-29b agomir abolished these elevations ( Fig. 2C and D) . Furthermore, echocardiographic examination showed that Dox treatment displayed changes in left ventricular morphology, characterized by left ventricular end-diastolic posterior wall thinning with increased left ventricular end-diastolic diameter. These parameters were significantly improved by miR-29b overexpression (Fig. 2E-G) . No significant differences were observed in left ventricular end-systolic diameter among the 4 experimental groups (Fig. 2H) . miR-29b upregulation also inhibited the decrease in ejection fraction and fractional shortening percentage, indicating improved cardiac function ( Fig. 2I  and J) . Additionally, miR-29b agomir-treated rats showed lower Dox-induced mortality (Fig.  2K) .
miR-29b upregulation attenuates Dox-induced myocardial apoptosis
Based on the protective effect of miR-29b against Dox-induced myocardial injury, we subsequently aimed to investigate the effect of miR-29b upregulation on myocardial apoptosis. Fig. 3A and B showed that the number of TUNEL-positive cells was significantly increased in myocardium of Dox-treated rats, which was diminished by miR-29b agomir but not MA. To understand how miR-29b inhibits myocardial apoptosis, the expression of apoptosisrelated molecules was examined. Dox insult dramatically decreased the expression of the anti-apoptotic protein Bcl-2 and increased the expression of the pro-apoptotic protein Bax in However, miR-29b agomir treatment resulted in higher Bcl-2 expression and lower Bax expression than that in Dox-treated rats ( Fig. 3C and D) . We also measured the changes in caspase-3 mRNA expression and activity. Dox administration increased the mRNA expression and activity of caspase-3. As expected, these elevations were markedly blocked by miR-29b treatment ( Fig. 3E and F) . These results indicate that the inhibition of apoptosis may contribute to the protective effect of miR-29b against myocardial injury.
miR-29b overexpression mitigates Dox-induced cardiomyocyte apoptosis in vitro
We next tried to confirm whether the anti-apoptotic effects of miR-29b in myocardium also existed in vitro under Dox stimulation. The CCK-8 assay showed that Dox treatment significantly decreased the viability of cardiomyocytes, which was suppressed by miR-29b overexpression induced by miR-29b agomir. By contrast, inhibition of miR-29b by miR29b inhibitor potentiated the decrease in cell viability (Fig. 4A) . Similarly, LDH release in cardiomyocytes was also markedly increased after Dox challenge. Overexpression of miR29b suppressed, whereas miR-29b inhibition enhanced, the Dox-induced release of LDH (Fig. 4B) . The annexin V-FITC/PI data showed that Dox treatment induced an increase in the apoptotic rate from 11.5% ± 2.3% to 29.5% ± 3.0% in cardiomyocytes when compared with the vehicle group. Upregulation of miR-29b decreased the apoptotic cell rate to 17.6% ± 2.1%, whereas miR-29b inhibition further increased the apoptotic rate to 43.3% ± 4.9% (Fig.  4C and D) . Similar to the results of flow cytometry, miR-29b upregulation resulted in fewer TUNEL-positive cells compared with Dox treatment alone. However, inhibition of miR-29b showed the opposite effect ( Fig. 4E and F) . 
miR-29b directly targets the Bax 3′-UTR
Computational mRNA target analysis (www.Targetscan.org) showed that Bax is a potential molecular target of miR-29b. The miR-29b binding site in the Bax 3′-UTR is conserved among human, chimpanzee, rhesus monkey, mouse, and rat (Fig. 5A) . To confirm whether miR-29b can decrease Bax expression through direct 3′-UTR interaction, we generated a firefly luciferase reporter plasmid containing the Bax 3′-UTR and performed reporter analysis. By co-transfection of the reporter plasmid with miR-29b mimics, miR29b inhibitor, or their corresponding negative controls, and Bax 3′-UTR or the mutant in cardiomyocytes, the luciferase assay showed that miR-29b overexpression significantly decreased the luciferase activity of the Bax 3′-UTR. However, miR-29b mimics failed to affect the luciferase activity elicited by the reporter carrying the Bax 3′-UTR with the mutant miR29b binding site (Fig. 5B) . In contrast, inhibition of miR-29b increased the luciferase activity of the Bax 3′-UTR, but also had no effect on the mutant (Fig. 5C ). In agreement with the above observations, miR-29b upregulation effectively decreased the mRNA expression of Bax, whereas downregulation of miR-29b increased Bax mRNA expression in cardiomyocytes ( Fig. 5D and E) . Furthermore, the protein expression of Bax after miR-29 mimics or inhibitor transfection showed similar changes in mRNA expression ( Fig. 5F and G) . Taken together, these results demonstrate that Bax is the target gene of miR-29b.
Mitochondria-dependent pathway is involved in miR-29b-mediated cardiomyocyte apoptosis
Consistent with the results in vivo, Dox treatment for 24 h obviously decreased Bcl-2 expression and increased Bax expression, resulting in a decrease in the Bcl-2/Bax ratio. Overexpression of miR-29b attenuated the effect of Dox on Bcl-2 and Bax expression and the Bcl-2/Bax ratio. However, miR-29b inhibition further enhanced Bax expression and reduced Bcl-2 expression and the Bcl-2/Bax ratio (Fig. 6A-D) . Imbalance between Bcl-2 and Bax expression has been suggested to be associated with mitochondria dysfunction [20] . -- 
Bcl-2/Bax
Therefore, we further examined whether miR-29b could influence MMP in cardiomyocytes by JC-1 staining. Confocal microscopy showed that Dox decreased red fluorescence and increased green fluorescence, leading to a decrease in the red/green fluorescence intensity ratio as compared with the vehicle group, indicating a loss of MMP. Inhibition of miR-29b markedly enhanced the Dox-induced loss of MMP, and inverse results were obtained in cells treated with miR-29b agomir (Fig. 6E and F) . It has been documented that the increase in MMP induces cytochrome c release from mitochondria to the cytoplasm and subsequently results in caspase cascade activation [21] . Western blotting showed that the translocation of cytochrome c from mitochondria to cytoplasm was dramatically increased after Dox challenge, which was blocked by miR-29b agomir (Fig. 6G) . In contrast, miR-29b inhibition further promoted the translocation of cytochrome c induced by Dox (Fig. 6G ). In parallel with this, Dox treatment significantly increased caspase-9, caspase-3, and PARP cleavage. Overexpression of miR-29b inhibited, whereas miR-29b inhibition further increased, the activation of caspase-9, caspase-3, and PARP (Fig. 6I-K) . Collectively, these data indicate that miR-29b attenuates Dox-induced cardiomyocyte apoptosis at least in part through inhibiting the mitochondria-dependent pathway.
Discussion
Cardiomyocyte apoptosis is a major feature of Dox cardiotoxicity. Herein, we provide evidence that miR-29b is downregulated in response to Dox treatment and attenuates cardiotoxicity associated with cardiomyocyte apoptosis. In support of this evidence, using gain-and loss-of-function approaches, we found that miR-29b inhibits the mitochondriadependent apoptotic pathway by directly targeting Bax, an effect that reduces the Bax/Bcl-2 ratio and cytochrome c release, and attenuates caspase cascade activation. With regard to these results, our study identifies miR-29b as a critical regulator of cardiomyocyte apoptosis induced by Dox.
miR-29b belongs to the miR-29 family, which includes 3 mature miRNAs: miR-29a, miR29b (miR-29b-1 and miR-29b-2), and miR-29c. These mature sequences are transcribed from two different gene clusters located on two different chromosomes, respectively [22, 23] . miR-29b-1 and miR-29b-2 (herein referred to as miR-29b) share the same mature sequence, while miR-29a and miR-29c differ by one nucleotide [24] . This miR family has been well recognized as an important regulator of collagen expression and heart fibrosis [25, 26] . More recent studies revealed that miR-29a and miR-29b regulate apoptosis by targeting different genes [27, 28] . Altered expression of miR-29b has been detected in multiple tumors and leukemia [28, 29] , raising the intriguing possibility that aberrant miR-29b expression and/or function may be associated with dysfunction of the apoptosisrelated pathway. Recent studies have demonstrated that miR-29a and miR-29c are involved in neuronal apoptosis and the serum levels of these miRs are negatively correlated with Parkinson's disease severity [24, 30, 31] . Han et al. reported that miR-29a regulated high glucose-induced myocardial cell apoptosis by targeting IGF-1 [32] . Swimming training exercise can induce miR-29c upregulation, which is related to a significant reduction in collagen gene expression and improvement of cardiac function [25] . In the present study, we found that miR-29b is highly expressed in myocardium compared with miR-29a and miR29c. Interestingly, its expression was dramatically decreased after Dox challenge in vivo and in vitro, indicating a potential role of miR-29b in Dox cardiotoxicity. By contrast, Leger et al. showed that miR-29b was upregulated in plasma of children and young adults 6 to 24 h after anthracycline administration [3] . Presumably, the discrepancy is probably related to (1) miR29b expression possibly having different roles in cardiotoxicity in different samples (plasma or myocardium) even under the same stimulation, and (2) the extent of cardiotoxicity as well as the change in miR-29b possibly being differentially induced by anthracycline compounds with different time periods. Dox is a highly potent chemotherapeutic agent. However, its potential usage is largely limited due to its cardiotoxicity, which was reported to be fatal in some cases [2, 6] . Dox cardiotoxicity features a reduction of ejection fraction and thinning and dilatation of the ventricular wall [8] . Here, we found a marked reduction in left ventricular end-diastolic posterior wall thickness, ejection fraction, and fractional shortening percentage in Dox-treated rats, concomitantly with increased cardiomyocyte membrane permeability and serum LDH concentration. This was consistent with previous studies in several animal models [8, 19, 33] . However, upregulation of miR-29b was effective in improving cardiac function. Also, miR29b agomir-treated rats significantly decreased the susceptibility to Dox-induced mortality. These data suggest that miR-29b can prevent Dox-induced cardiotoxicity. It is worth noting that inhibition of miR-29b led to an increase in collage gene expression and a subsequent decrease in aneurysm expansion [23, 34, 35] . In contrast, miR-29b overexpression increased abdominal aortic aneurysm (AAA) expansion and the aortic rupture rate [35] . These studies indicate a protective role of miR-29b inhibition during AAA development. However, given the significant role of miR-29b in the reduction of collagen expression, endogenous miR-29b diminished many fibrotic events, particularly in the heart, and addition of exogenous miR29b could also inhibit ventricular compliance development [9] . Thus, precise modulation of miR-29b expression seems to be of great importance in specific local tissues and different pathological processes, especially in cardiovascular diseases.
It has been suggested that Dox cardiotoxicity is well characterized by myocardial apoptosis, leading to loss of myocytes and deterioration of heart function [7, 8, 16] . miR-29 is an important regulator in cardiac physiology that diminishes extracellular matrix deposition and heart fibrosis [25, 26] . However, until now it was unclear whether there is a link between miR-29b and apoptosis in cardiomyocytes. In the present study, we observed a significant increase in myocardial apoptosis in Dox-treated rats, which was inhibited by miR-29b upregulation. This was further confirmed by overexpression of miR-29b using a miR-29b mimics in vitro, while miR-29b inhibition further promoted cardiomyocyte apoptosis. Several biochemical pathways, including disruption of intracellular calcium homeostasis, increased generation of reactive oxygen species, inhibition of anti-apoptotic proteins, and induction of pro-apoptotic proteins, have been shown to be associated with Dox-induced myocardial apoptosis and cardiotoxicity [5] . These cellular events are considered to induce apoptosis via the intrinsic pathway. The Bcl-2 family plays a key role in the apoptotic machinery and a variety of upstream survival signals. Bcl-2 is one of the important anti-apoptotic proteins, whereas Bax promotes apoptosis [20] . Thus, the Bcl-2/ Bax ratio determines the fate of cells [21, 27] . Moreover, caspase-3 has been confirmed as a dominant executor in the intrinsic pathway of apoptosis [21] . Here, our data demonstrated that miR-29b agomir treatment resulted in a marked increase in Bcl-2 and a decrease in Bax as well as downregulation of caspase activity and mRNA expression. It has been previously reported that miR-29a suppresses Bcl-2 and Mcl-1 expression and increases hepatocellular carcinoma cell, cholangiocarcinoma cell, and neuronal apoptosis [10, 22, 27] , suggesting an interaction between miR-29b and Bcl-2 or Mcl-1 in various cell types. These differences may be attributable to different mechanisms involved in and related to the regulation of specific cellular functions and disease states.
We next investigated the mechanism that allows miR-29b to ameliorate Dox-induced cardiomyocyte apoptosis. Our data showed that Bax is a novel target of miR-29b. miR-29b targeted the Bax 3′-UTR to decrease Bax expression, while inhibition of miR-29b significantly increased Bax expression. By binding to pore proteins on mitochondrial membranes, Bax can affect MMP, which leads to mitochondrial membrane depolarization and cytochrome c release from mitochondria to the cytoplasm [20] . The released cytochrome c combines with caspase-9 to form a complex and activates the caspase cascade, in which caspase-3 plays a dominant role [21, 36] . Upon DNA cleavage by caspase-3 activation, PARP depletes ATP in order to repair damaged DNA and maintain cell viability [5] . Depletion of ATP can result in cell lysis and death [36] . In this study, we found that overexpression of miR-29b in cardiomyocytes restored the loss of MMP induced by Dox, and decreased the release of Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry cytochrome c and cleaved caspase-3, caspase-9, and PARP. Inhibition of miR-29b, however, produced the opposite effects. These findings suggest that miR-29b upregulation inhibits the mitochondria-dependent pathway by directly targeting Bax.
In conclusion, this study demonstrates that, in addition to regulating heart fibrosis, miR29b also has an important role in myocardial apoptosis. We provide the first evidence to our knowledge of the anti-apoptotic property of miR-29b in cardiomyocytes, which offers a rational therapeutic strategy to combat cardiotoxicity and even heart failure during Dox treatment.
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